MLLT10
Protein AF-10
Protein Summary
Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. In cells, binding to unmodified histone H3 regulates DOT1L functions including histone H3 'Lys-79' dimethylation (H3K79me2) and gene activation (PubMed:26439302). This gene encodes a transcription factor and has been identified as a partner gene involved in several chromosomal rearrangements resulting in various leukemias. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2010]
- ENST00000307729
- ENSP00000307411
- ENSG00000078403
- ENST00000377059
- ENSP00000366258
- ENST00000377072
- ENSP00000366272
- ENST00000377091
- ENSP00000366295
- ENST00000377100
- ENSP00000366304
- ENST00000621220
- ENSP00000484335
- ENST00000631589
- ENSP00000488569
- AF10
- AF10
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
co-expressed gene | 1 | ||
transcription factor binding site profile | 0.92 | ||
transcription factor perturbation | 0.84 | ||
protein domain | 0.73 | ||
transcription factor | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 200.68 (req: < 5)
Gene RIFs: 25 (req: <= 3)
Antibodies: 355 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 200.68 (req: >= 5)
Gene RIFs: 25 (req: > 3)
Antibodies: 355 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0